Nicolas G. Sitchon
Nicolas G. Sitchon, M.A., M.B.A. has served as Chairman of our board of directors and as our President and Chief Executive Officer since our founding in October 2010. From October 2008 to October 2010, Mr. Sitchon performed services in anticipation of incorporation of our company and related to the development of our lead product candidate, LorexysTM. From April 2006 to October 2008, Mr. Sitchon was Global Research & Development Controller at Bayer HealthCare Consumer Care, a division of Bayer AG. Prior to that time, Mr. Sitchon held positions in marketing, information technology, business intelligence and business planning in the cardiovascular and neuroscience franchises of the Pharmaceuticals division of Novartis Corporation. Mr. Sitchon received his M.A. in Medical Science from the Boston University School of Medicine and his M.B.A. from the Boston University School of Management. He completed his undergraduate studies at the University of California, Berkeley. Mr. Sitchon was selected to serve as a member of our Board of Directors because of his role in developing, and his extensive knowledge regarding, our product candidates; his experience as our executive officer; because of his proven ability to pursue the development of product candidates in an efficient manner using minimal capital; and because of his advanced degrees in science and business.
Jane H. Hollingsworth
Jane H. Hollingsworth has served as a member of our board of directors since August 2014. Ms. Hollingsworth is currently Managing Partner of Militia Hill Ventures LLC, a privately held life sciences accelerator, a position she has held since October 2013, and Executive Chair of Immunome Inc., a privately held cancer immunotherapy company, a position she has held since October 2013. From October 2012 to December 2013, Ms. Hollingsworth was the President of JHH Technologies LLC, a privately held company offering advisory healthcare services. She served as CEO and was a co-founder of NuPathe Inc., a publicly traded biopharmaceutical company focused on diseases of the central nervous system, from January 2005 to September 2007. Prior to joining NuPathe Inc., Ms. Hollingsworth served as Executive Vice President and was a co-founder of Auxilium Pharmaceuticals Inc., a publicly traded biopharmaceutical company, and Vice President, Secretary and General Counsel of IBAH , Inc., a publicly traded clinical research organization that was sold to Omnicare Inc. in 1998. Ms. Hollingsworth began her career as a commercial litigator at the law firm of Montgomery, McCracken, Walker & Rhoads and as law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware. Ms. Hollingsworth received her B.A. degree in Spanish from Gettysburg College and her J.D. from Villanova University. Ms. Hollingsworth was selected to serve as a member of our Board of Directors because of her significant experience in the life sciences industry and as an executive officer of biotechnology and healthcare companies, including publicly-traded companies.
Gregg A. Lapointe
Gregg A. Lapointe, CPA has served as a member of our board of directors since August 2014. Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc., a specialty pharmaceutical company, a position he has held since April 2012. Mr. Lapointe also currently serves on the Board of Directors of Soligenix, Inc., a publicly traded biopharmaceutical company, SciClone Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company, and Cambrooke Therapeutics, Inc., a privately held therapeutic nutrition company, and the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. He has previously served on the Board of Directors of the Pharmaceuticals Research and Manufacturers of America (PhRMA) and Questcor Pharmaceuticals, Inc., and has been a member of the Corporate Council of NORD (National Organization for Rare Disorders) for several years. He previously served in varying roles for Sigma-Tau Pharmaceuticals, Inc, a private biopharmaceutical company, from September 2001 through February 2012, including Chief Operating Officer from November 2003 to April 2008 and Chief Executive Officer from April 2008 to February 2012. From May, 1996 to August, 2001, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc., a global manufacturer of paper machine clothing, advanced and filtration fabrics, filaments and drainage equipment). Prior to that, Mr. Lapointe spent several years in the Canadian medical products industry in both distribution and manufacturing. Mr. Lapointe began his career at Price Waterhouse. Mr. Lapointe received his B.A. degree in Commerce from Concordia University in Montreal, Canada, a graduate diploma in Accountancy from McGill University and his M.B.A. degree from Duke University. He is a C.P.A. in the state of Illinois and a Chartered Accountant in Ontario, Canada. Mr. Lapointe was selected to serve as a member of our Board of Directors because of his significant experience in the areas of global strategic planning and implementation, business development, corporate finance, and acquisitions, and his experience as an executive officer and board member in the pharmaceutical and medical products industries.